Cantor Fitzgerald Estimates Atyr PHARMA FY2025 Earnings

Atyr PHARMA INC (NASDAQ:ATYR) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Atyr PHARMA in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal expects that the company will post earnings of ($0.87) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.91) per share.

Atyr PHARMA (NASDAQ:ATYR) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01).

ATYR has been the subject of a number of other research reports. Wells Fargo & Company initiated coverage on Atyr PHARMA in a research note on Friday, October 4th. They issued an “overweight” rating and a $17.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a research report on Tuesday, December 10th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $19.25.

Atyr PHARMA Trading Down 3.6 %

NASDAQ ATYR opened at $3.50 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $4.22. The company has a market cap of $293.80 million, a PE ratio of -3.72 and a beta of 1.08. The business’s 50 day moving average price is $3.40.

Hedge Funds Weigh In On Atyr PHARMA

An institutional investor recently raised its position in Atyr PHARMA stock. JPMorgan Chase & Co. raised its position in shares of Atyr PHARMA INC (NASDAQ:ATYR) by 52.0% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 31,440 shares of the company’s stock after acquiring an additional 10,754 shares during the period. JPMorgan Chase & Co.’s holdings in Atyr PHARMA were worth $55,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.